NR3C1 |
A549 (lung carcinoma) |
1 h with 500 pM Dexamethasone (Myers) |
Permissive
|
Homo sapiens |
ENCSR000BHE
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
1 h with 50 nM Dexamethasone (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR000BHF
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
1 h with 5 nM Dexamethasone (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR000BHG
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
1 h with 0.02% Ethanol (Myers) |
Permissive
|
Homo sapiens |
ENCSR000BIO
|
MA0113.3
|
NR3C1 |
Ishikawa (endometrial adenocarcinoma) |
1 h with 100 nM Dexamethasone (Myers) |
Permissive
|
Homo sapiens |
ENCSR000BJC
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
1 h with 100 nM Dexamethasone (Myers) |
Permissive
Robust
|
Homo sapiens |
ENCSR000BJR
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
1 h with 0.02% Ethanol (Myers) |
Permissive
|
Homo sapiens |
ENCSR000BJT
|
MA0113.3
|
NR3C1 |
Ishikawa (endometrial adenocarcinoma) |
1 h with 0.02% Ethanol (Myers) |
Permissive
|
Homo sapiens |
ENCSR000BLB
|
MA0113.3
|
NR3C1 |
HepG2 (hepatoblastoma) |
low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder) |
Permissive
Robust
|
Homo sapiens |
ENCSR000EEV
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 20 minute |
Permissive
Robust
|
Homo sapiens |
ENCSR458VTP
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 10 minute |
Permissive
Robust
|
Homo sapiens |
ENCSR471EKW
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 25 minute |
Permissive
Robust
|
Homo sapiens |
ENCSR070VXO
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 15 minute |
Permissive
Robust
|
Homo sapiens |
ENCSR908AOO
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 5 minute |
Permissive
Robust
|
Homo sapiens |
ENCSR857QEA
|
MA0113.3
|
NR3C1 |
3T3-L1-derived preadipocytes |
4 hours of differentiation |
Permissive
Robust
|
Mus musculus |
GSE27826
...
|
MA0113.3
|
NR3C1 |
BMDM (bone marrow-derived macrophages) |
Dexamethasone treated, unstimulated |
Permissive
Robust
|
Mus musculus |
GSE31796
...
|
MA0113.3
|
NR3C1 |
BMDM (bone marrow-derived macrophages) |
Dexamethasone treated, LPS-stimulated |
Permissive
Robust
|
Mus musculus |
GSE31796
...
|
MA0113.3
|
NR3C1 |
BMDM (bone marrow-derived macrophages) |
LPS-stimulated macrophages |
Permissive
|
Mus musculus |
GSE31796
...
|
MA0113.3
|
NR3C1 |
BMDM (bone marrow-derived macrophages) |
Dexamethasone treated, LPS-stimulated macrophages |
Permissive
|
Mus musculus |
GSE31796
...
|
MA0113.3
|
NR3C1 |
LNCaP (prostate carcinoma) |
100 nM DEX |
Permissive
Robust
|
Homo sapiens |
GSE39879
...
|
MA0113.3
|
NR3C1 |
VCaP (prostate carcinoma) |
100 nM DEX |
Permissive
|
Homo sapiens |
GSE39879
...
|
MA0113.3
|
NR3C1 |
LNCaP (prostate carcinoma) |
100 nM Dex |
Permissive
Robust
|
Homo sapiens |
GSE39879
...
|
MA0113.3
|
NR3C1 |
LNCaP (prostate carcinoma) |
100 nM DHT+Dex |
Permissive
Robust
|
Homo sapiens |
GSE39879
...
|
MA0113.3
|
NR3C1 |
AtT-20 (pituitary tumor) |
Dex |
Permissive
Robust
|
Mus musculus |
GSE37235
...
|
MA0113.3
|
NR3C1 |
liver |
Ad-lib fed |
Permissive
Robust
|
Mus musculus |
GSE45674
...
|
MA0113.3
|
NR3C1 |
liver |
veh |
Permissive
|
Mus musculus |
GSE46047
...
|
MA0113.3
|
NR3C1 |
liver |
dex |
Permissive
Robust
|
Mus musculus |
GSE46047
...
|
MA0113.3
|
NR3C1 |
liver |
dex adGFP |
Permissive
Robust
|
Mus musculus |
GSE46047
...
|
MA0113.3
|
NR3C1 |
liver |
dex adDN-C/EBP |
Permissive
Robust
|
Mus musculus |
GSE46047
...
|
MA0113.3
|
NR3C1 |
mammary cells |
untreated |
Permissive
|
Mus musculus |
GSE46123
...
|
MA0113.3
|
NR3C1 |
mammary cells |
Dexamethasone for 30 minutes |
Permissive
Robust
|
Mus musculus |
GSE46123
...
|
MA0113.3
|
NR3C1 |
mammary cells |
Estradiol for 30 minutes |
Permissive
|
Mus musculus |
GSE46123
...
|
MA0113.3
|
NR3C1 |
mammary cells |
Dexamethasone + Estradiol for 30 minutes |
Permissive
Robust
|
Mus musculus |
GSE46123
...
|
MA0113.3
|
NR3C1 |
7438 (mammary carcinoma) |
untreated |
Permissive
|
Mus musculus |
GSE46123
...
|
MA0113.3
|
NR3C1 |
7438 (mammary carcinoma) |
Dexamethasone for 30 minutes |
Permissive
Robust
|
Mus musculus |
GSE46123
...
|
MA0113.3
|
NR3C1 |
7438 (mammary carcinoma) |
Estradiol for 30 minutes |
Permissive
Robust
|
Mus musculus |
GSE46123
...
|
MA0113.3
|
NR3C1 |
7438 (mammary carcinoma) |
Dexamethasone + Estradiol for 30 minutes |
Permissive
Robust
|
Mus musculus |
GSE46123
...
|
MA0113.3
|
NR3C1 |
embryonic kidney |
dexamethasone |
Permissive
Robust
|
Homo sapiens |
GSE48374
...
|
MA0113.3
|
NR3C1 |
embryonic kidney |
dexamethasone, stably expressing wt GR |
Permissive
Robust
|
Homo sapiens |
GSE48374
...
|
MA0113.3
|
NR3C1 |
embryonic kidney |
dexamethasone, stably expressing SUMOylation-defective GR |
Permissive
Robust
|
Homo sapiens |
GSE48374
...
|
MA0113.3
|
NR3C1 |
MDA-MB-231 (breast adenocarcinoma) |
dexametasone |
Permissive
Robust
|
Homo sapiens |
GSE56022
...
|
MA0113.3
|
NR3C1 |
MDA-MB-231 (breast adenocarcinoma) |
compaund A |
Permissive
|
Homo sapiens |
GSE56022
...
|
MA0113.3
|
NR3C1 |
acute myeloblastic leukemia |
dexametasone |
Permissive
Robust
|
Homo sapiens |
GSE58266
...
|
MA0113.3
|
NR3C1 |
liver |
none |
Permissive
|
Mus musculus |
GSE59752
...
|
MA0113.3
|
NR3C1 |
liver |
none |
Permissive
|
Mus musculus |
GSE59752
...
|
MA0113.3
|
NR3C1 |
liver |
prednisolone |
Permissive
|
Mus musculus |
GSE59752
...
|
MA0113.3
|
NR3C1 |
liver |
none |
Permissive
Robust
|
Mus musculus |
GSE59752
...
|
MA0113.3
|
NR3C1 |
liver |
none |
Permissive
Robust
|
Mus musculus |
GSE59752
...
|
MA0113.3
|
NR3C1 |
liver |
prednisolone |
Permissive
Robust
|
Mus musculus |
GSE59752
...
|
MA0113.3
|
NR3C1 |
BMDM (bone marrow-derived macrophages) |
dexamethasone and (or) lipopolysaccharide |
Permissive
Robust
|
Mus musculus |
GSE59764
...
|
MA0113.3
|
NR3C1 |
BMDM (bone marrow-derived macrophages) |
dexamethasone and (or) lipopolysaccharide |
Permissive
|
Mus musculus |
GSE59764
...
|
MA0113.3
|
NR3C1 |
3134 (mammary adenocarcinoma) |
cort for 20min |
Permissive
Robust
|
Mus musculus |
GSE61234
...
|
MA0113.3
|
NR3C1 |
3134 (mammary adenocarcinoma) |
cort pulsed 60min |
Permissive
Robust
|
Mus musculus |
GSE61234
...
|
MA0113.3
|
NR3C1 |
3134 (mammary adenocarcinoma) |
cort constant 60min |
Permissive
Robust
|
Mus musculus |
GSE61234
...
|
MA0113.3
|
NR3C1 |
retina |
dex |
Permissive
Robust
|
Mus musculus |
GSE61877
...
|
MA0113.3
|
NR3C1 |
burst-forming unit erythroid |
Dexamethasone 4 hrs |
Permissive
|
Mus musculus |
GSE62788
...
|
MA0113.3
|
NR3C1 |
burst-forming unit erythroid |
Dexamethasone and GW7647 4 hrs |
Permissive
|
Mus musculus |
GSE62788
...
|
MA0113.3
|
NR3C1 |
HEK293T (embryonic kidney) |
Dexamethasone (24h) |
Permissive
|
Homo sapiens |
GSE64171
...
|
MA0113.3
|
NR3C1 |
white adipose tissue |
standard rodent chow diet |
Permissive
Robust
|
Mus musculus |
GSE64458
...
|
MA0113.3
|
NR3C1 |
inguinal white adipose tissue |
standard rodent chow diet |
Permissive
Robust
|
Mus musculus |
GSE64458
...
|
MA0113.3
|
NR3C1 |
embryonic fibroblasts |
dexametasone |
Permissive
Robust
|
Mus musculus |
GSE69947
...
|
MA0113.3
|
NR3C1 |
embryonic fibroblasts |
Klf15 -/- |
Permissive
|
Mus musculus |
GSE69947
...
|
MA0113.3
|
NR3C1 |
embryonic fibroblasts |
dexametasone, Klf15 -/- |
Permissive
|
Mus musculus |
GSE69947
...
|
MA0113.3
|
NR3C1 |
mammary gland |
lactation day 1, Wap-delE1a |
Permissive
Robust
|
Mus musculus |
GSE74826
...
|
MA0113.3
|
NR3C1 |
mammary gland |
lactation day 1, Wap-delE1b |
Permissive
|
Mus musculus |
GSE74826
...
|
MA0113.3
|
NR3C1 |
mammary gland |
lactation day 1, Wap-delE1c |
Permissive
Robust
|
Mus musculus |
GSE74826
...
|
MA0113.3
|
NR3C1 |
mammary gland |
lactation day 1, Wap-delE2 |
Permissive
Robust
|
Mus musculus |
GSE74826
...
|
MA0113.3
|
NR3C1 |
mammary gland |
lactation day 1, Wap-delE3 |
Permissive
Robust
|
Mus musculus |
GSE74826
...
|
MA0113.3
|
NR3C1 |
mammary gland |
lactation day 1 |
Permissive
Robust
|
Mus musculus |
GSE74826
...
|
MA0113.3
|
NR3C1 |
mammary gland |
pregnancy day 13 |
Permissive
|
Mus musculus |
GSE74826
...
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
dex |
Permissive
|
Homo sapiens |
GSE79431
...
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
etoh |
Permissive
Robust
|
Homo sapiens |
GSE79431
...
|
MA0113.3
|
NR3C1 |
BEAS-2B (bronchial epithelium) |
dexamethasone |
Permissive
Robust
|
Homo sapiens |
GSE79803
...
|
MA0113.3
|
NR3C1 |
BEAS-2B (bronchial epithelium) |
dexamethasone + TNF |
Permissive
Robust
|
Homo sapiens |
GSE79803
...
|
MA0113.3
|
NR3C1 |
BEAS-2B (bronchial epithelium) |
vehicle |
Permissive
|
Homo sapiens |
GSE79803
...
|
MA0113.3
|
NR3C1 |
mammary gland |
lactation day one |
Permissive
Robust
|
Mus musculus |
GSE84115
...
|
MA0113.3
|
NR3C1 |
mammary gland |
involution 12 hours |
Permissive
|
Mus musculus |
GSE84115
...
|
MA0113.3
|
NR3C1 |
mammary gland |
involution 24 hours |
Permissive
|
Mus musculus |
GSE84115
...
|
MA0113.3
|
NR3C1 |
hepatocytes |
fed 10 h |
Permissive
Robust
|
Mus musculus |
GSE72084
...
|
MA0113.3
|
NR3C1 |
hepatocytes |
fasted 24 h |
Permissive
Robust
|
Mus musculus |
GSE72084
...
|
MA0113.3
|
NR3C1 |
hepatocytes |
glucagon (10nM) + corticosterone (1.7uM) for 1hr |
Permissive
Robust
|
Mus musculus |
GSE72084
...
|
MA0113.3
|
NR3C1 |
brown preadipocytes |
GR KO |
Permissive
|
Mus musculus |
GSE76619
...
|
MA0113.3
|
NR3C1 |
MCF7 (Invasive ductal breast carcinoma) |
ICI |
Permissive
|
Homo sapiens |
GSE81510
...
|
MA0113.3
|
NR3C1 |
MCF7 (Invasive ductal breast carcinoma) |
ICI, DEX |
Permissive
Robust
|
Homo sapiens |
GSE81510
...
|
MA0113.3
|
NR3C1 |
MCF7 (Invasive ductal breast carcinoma) |
E2 |
Permissive
|
Homo sapiens |
GSE81510
...
|
MA0113.3
|
NR3C1 |
MCF7 (Invasive ductal breast carcinoma) |
E2, DEX |
Permissive
Robust
|
Homo sapiens |
GSE81510
...
|
MA0113.3
|
NR3C1 |
MCF7 (Invasive ductal breast carcinoma) |
ICI, pBox mutant |
Permissive
|
Homo sapiens |
GSE81510
...
|
MA0113.3
|
NR3C1 |
MCF7 (Invasive ductal breast carcinoma) |
ICI, DEX, pBox mutant |
Permissive
Robust
|
Homo sapiens |
GSE81510
...
|
MA0113.3
|
NR3C1 |
MCF7 (Invasive ductal breast carcinoma) |
E2, pBox mutant |
Permissive
|
Homo sapiens |
GSE81510
...
|
MA0113.3
|
NR3C1 |
MCF7 (Invasive ductal breast carcinoma) |
E2, DEX, pBox mutant |
Permissive
|
Homo sapiens |
GSE81510
...
|
MA0113.3
|
NR3C1 |
mammary gland |
Socs2 mut, pregnancy day13 |
Permissive
Robust
|
Mus musculus |
GSE82275
...
|
MA0113.3
|
NR3C1 |
mammary gland |
delA mutant |
Permissive
Robust
|
Mus musculus |
GSE92591
...
|
MA0113.3
|
NR3C1 |
mammary gland |
delC mutant |
Permissive
Robust
|
Mus musculus |
GSE92591
...
|
MA0113.3
|
NR3C1 |
bone marrow-derived macrophages |
Dex/DSG+FA |
Permissive
Robust
|
Mus musculus |
GSE93736
...
|
MA0113.3
|
NR3C1 |
bone marrow-derived macrophages |
LPS+Dex/DSG+FA |
Permissive
Robust
|
Mus musculus |
GSE93736
...
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 7 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR952GOL
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 12 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR287FWE
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 3 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR385RUW
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 6 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR424JOE
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 4 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR660RYY
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 5 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR686PFM
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 30 minute |
Permissive
Robust
|
Homo sapiens |
ENCSR773NQB
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 10 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR255CTA
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
100nM dexamethasone (CHEBI:41879) for 8 hour |
Permissive
Robust
|
Homo sapiens |
ENCSR691GRA
|
MA0113.3
|
NR3C1 |
MCF-7 C4-12 (invasive breast ductal carcinoma) |
Female |
Permissive
Robust
|
Homo sapiens |
GSE104399
...
|
MA0113.3
|
NR3C1 |
breast tumor |
Male |
Permissive
Robust
|
Homo sapiens |
GSE104399
...
|
MA0113.3
|
NR3C1 |
MCF10A (breast epithelial cells) |
Treatment: untreated; |
Permissive
Robust
|
Homo sapiens |
GSE102355
...
|
MA0113.3
|
NR3C1 |
MCF10A (breast epithelial cells) |
Treatment: untreated; |
Permissive
Robust
|
Homo sapiens |
GSE102355
...
|
MA0113.3
|
NR3C1 |
MCF10A (breast epithelial cells) |
Treatment: dexamethasone (DEX) 20 min; |
Permissive
Robust
|
Homo sapiens |
GSE102355
...
|
MA0113.3
|
NR3C1 |
MCF10A (breast epithelial cells) |
Treatment: dexamethasone (DEX) 20 min; |
Permissive
Robust
|
Homo sapiens |
GSE102355
...
|
MA0113.3
|
NR3C1 |
MCF10A (breast epithelial cells) |
Treatment: dexamethasone (DEX) 60 min; |
Permissive
Robust
|
Homo sapiens |
GSE102355
...
|
MA0113.3
|
NR3C1 |
MCF10A (breast epithelial cells) |
Treatment: dexamethasone (DEX) 60 min; |
Permissive
Robust
|
Homo sapiens |
GSE102355
...
|
MA0113.3
|
NR3C1 |
MCF10A (breast epithelial cells) |
Treatment: EGF + DEX 20 min; |
Permissive
Robust
|
Homo sapiens |
GSE102355
...
|
MA0113.3
|
NR3C1 |
MCF10A (breast epithelial cells) |
Treatment: EGF + DEX 20 min; |
Permissive
Robust
|
Homo sapiens |
GSE102355
...
|
MA0113.3
|
NR3C1 |
MCF10A (breast epithelial cells) |
Treatment: EGF + DEX 60 min; |
Permissive
Robust
|
Homo sapiens |
GSE102355
...
|
MA0113.3
|
NR3C1 |
MCF10A (breast epithelial cells) |
Treatment: EGF + DEX 60 min; |
Permissive
Robust
|
Homo sapiens |
GSE102355
...
|
MA0113.3
|
NR3C1 |
Ishikawa (endometrial adenocarcinoma) |
Treatment: 100 nM Dexamethasone and 10 nM Estradiol for 1 hour |
Permissive
Robust
|
Homo sapiens |
GSE109891
...
|
MA0113.3
|
NR3C1 |
Ishikawa (endometrial adenocarcinoma) |
Treatment: 100 nM Dexamethasone for 1 hour |
Permissive
Robust
|
Homo sapiens |
GSE109891
...
|
MA0113.3
|
NR3C1 |
Ishikawa (endometrial adenocarcinoma) |
Treatment: DMSO (vehicle) for 1 hour |
Permissive
|
Homo sapiens |
GSE109891
...
|
MA0113.3
|
NR3C1 |
A1-2 (breast cancer cells) |
Treatment: 1hr EtOH |
Permissive
|
Homo sapiens |
GSE112491
...
|
MA0113.3
|
NR3C1 |
A1-2 (breast cancer cells) |
Treatment: 1hr Dex |
Permissive
Robust
|
Homo sapiens |
GSE112491
...
|
MA0113.3
|
NR3C1 |
HASM2 (Human airway smooth muscle 2) |
Treatment: EtOH for 4 hr |
Permissive
|
Homo sapiens |
GSE95632
...
|
MA0113.3
|
NR3C1 |
HASM2 (Human airway smooth muscle 2) |
Treatment: EtOH for 4 hr |
Permissive
|
Homo sapiens |
GSE95632
...
|
MA0113.3
|
NR3C1 |
HASM2 (Human airway smooth muscle 2) |
Treatment: dexamethasone for 4 hr |
Permissive
Robust
|
Homo sapiens |
GSE95632
...
|
MA0113.3
|
NR3C1 |
HASM2 (Human airway smooth muscle 2) |
Treatment: dexamethasone for 4 hr |
Permissive
Robust
|
Homo sapiens |
GSE95632
...
|
MA0113.3
|
NR3C1 |
HASM2 (Human airway smooth muscle 2) |
Treatment: dexamethasone for 4 hr Genotype: Ad-GFP transduction |
Permissive
Robust
|
Homo sapiens |
GSE95632
...
|
MA0113.3
|
NR3C1 |
HASM2 (Human airway smooth muscle 2) |
Treatment: dexamethasone for 4 hr Genotype: Ad-GFP transduction |
Permissive
Robust
|
Homo sapiens |
GSE95632
...
|
MA0113.3
|
NR3C1 |
HASM2 (Human airway smooth muscle 2) |
Treatment: dexamethasone for 4 hr Genotype: Ad-KLF15 transduction |
Permissive
Robust
|
Homo sapiens |
GSE95632
...
|
MA0113.3
|
NR3C1 |
HASM2 (Human airway smooth muscle 2) |
Treatment: dexamethasone for 4 hr Genotype: Ad-KLF15 transduction |
Permissive
Robust
|
Homo sapiens |
GSE95632
...
|
MA0113.3
|
NR3C1 |
granulocyte macrophage progenitors |
Treatment: untreated Tissue: bone marrow -derived Age: 8-10 weeks Sex: male Strain: C57BL/6 |
Permissive
|
Mus musculus |
GSE99887
...
|
MA0113.3
|
NR3C1 |
granulocyte macrophage progenitors |
Treatment: Dex, 100nm, 45 min Tissue: bone marrow -derived Age: 8-10 weeks Sex: male Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE99887
...
|
MA0113.3
|
NR3C1 |
THP-1 (acute monocytic leukemia) |
Treatment: untreated Tissue: peripheral blood-derived Sex: male |
Permissive
|
Homo sapiens |
GSE99887
...
|
MA0113.3
|
NR3C1 |
THP-1 (acute monocytic leukemia) |
Treatment: Dex, 100 nM, 1hour Tissue: peripheral blood-derived Sex: male |
Permissive
Robust
|
Homo sapiens |
GSE99887
...
|
MA0113.3
|
NR3C1 |
BMDM (bone marrow-derived macrophages) |
Treatment: 100 nM Dex for 45 minutes Age: 8-12 weeks Sex: male Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109131
...
|
MA0113.3
|
NR3C1 |
BMDM (bone marrow-derived macrophages) |
Treatment: 100 nM LPS for 45 minutes Age: 8-12 weeks Sex: male Strain: C57BL/6 |
Permissive
|
Mus musculus |
GSE109131
...
|
MA0113.3
|
NR3C1 |
BMDM (bone marrow-derived macrophages) |
Treatment: 10 ng/ml LPS + 100 nM Dex for 45 minutes Age: 8-12 weeks Sex: male Strain: C57BL/6 |
Permissive
Robust
|
Mus musculus |
GSE109131
...
|
MA0113.3
|
NR3C1 |
BMDM (bone marrow-derived macrophages) |
Treatment: untrated Age: 8-12 weeks Sex: male Strain: C57BL/6 |
Permissive
|
Mus musculus |
GSE109131
...
|
MA0113.3
|
NR3C1 |
mammary gland |
Wap-delE1; Lactation day 1 |
Permissive
|
Mus musculus |
GSE115368
...
|
MA0113.3
|
NR3C1 |
mammary gland |
Wap-delE1-delE2-delE3; Lactation day 1 |
Permissive
|
Mus musculus |
GSE115368
...
|
MA0113.3
|
NR3C1 |
kidney |
WT; lactation day 10 |
Permissive
Robust
|
Mus musculus |
GSE115368
...
|
MA0113.3
|
NR3C1 |
kidney |
Wap-E12-Ramp3; lactation day 10 |
Permissive
Robust
|
Mus musculus |
GSE115368
...
|
MA0113.3
|
NR3C1 |
mammary gland |
Wap-delE1-delE2-delE3; lactation day 10 |
Permissive
Robust
|
Mus musculus |
GSE115368
...
|
MA0113.3
|
NR3C1 |
mammary gland |
Wap-delE1-delE3; Lactation day 10 |
Permissive
Robust
|
Mus musculus |
GSE115368
...
|
MA0113.3
|
NR3C1 |
mammary gland |
Wap-delE1-delE3; Lactation day 1 |
Permissive
|
Mus musculus |
GSE115368
...
|
MA0113.3
|
NR3C1 |
mammary gland |
Wap-delE1; Lactation day 10 |
Permissive
Robust
|
Mus musculus |
GSE115368
...
|
MA0113.3
|
NR3C1 |
mammary gland |
WT; Lactation day 10 |
Permissive
Robust
|
Mus musculus |
GSE115368
...
|
MA0113.3
|
NR3C1 |
mammary gland |
WT; Lactation day 1 |
Permissive
|
Mus musculus |
GSE115368
...
|
MA0113.3
|
NR3C1 |
AtT-20 (pituitary tumor) |
Treatment: 30 minutes LIF and Dexamethasone Cell type: pituitary corticotroph cell Passage: 10-20 Genotype: expressing 3x flag-Neo |
Permissive
Robust
|
Mus musculus |
GSE87180
...
|
MA0113.3
|
NR3C1 |
AtT-20 (pituitary tumor) |
Treatment: 30 minutes LIF and Dexamethasone Cell type: pituitary corticotroph cell Passage: 10-20 Genotype: expressing 3x flag-Pax7 |
Permissive
Robust
|
Mus musculus |
GSE87180
...
|
MA0113.3
|
NR3C1 |
SUP-B15 (Childhood B acute lymphoblastic leukemia) |
Treatment: 90min with 0.02% ethanol Genotype: traslocation t(9;22)(q34;11) ? BCR-ABL1 e1-a2 fusion |
Permissive
|
Homo sapiens |
GSE107584
...
|
MA0113.3
|
NR3C1 |
SUP-B15 (Childhood B acute lymphoblastic leukemia) |
Treatment: 1uM dexamethasone in 0.02% ethanol Genotype: traslocation t(9;22)(q34;11) ? BCR-ABL1 e1-a2 fusion |
Permissive
Robust
|
Homo sapiens |
GSE107584
...
|
MA0113.3
|
NR3C1 |
liver |
Strain: C57BL/6 Genotype: wild type Treament: pre-prandial injection with vehicle |
Permissive
Robust
|
Mus musculus |
GSE119713
...
|
MA0113.3
|
NR3C1 |
liver |
Strain: C57BL/6 Genotype: wild type Treament: Night restricted feeding, pre-prandial injection with vehicle |
Permissive
Robust
|
Mus musculus |
GSE119713
...
|
MA0113.3
|
NR3C1 |
liver |
Strain: C57BL/6 Genotype: wild type Treament: Night restricted feeding, pre-prandial injection with 1mg/kg dex |
Permissive
Robust
|
Mus musculus |
GSE119713
...
|
MA0113.3
|
NR3C1 |
liver |
Strain: C57BL/6 Genotype: wild type Treament: none |
Permissive
Robust
|
Mus musculus |
GSE119713
...
|
MA0113.3
|
NR3C1 |
liver |
Strain: C57BL/6 Genotype: wild type Treament: Night restricted feeding |
Permissive
Robust
|
Mus musculus |
GSE119713
...
|
MA0113.3
|
NR3C1 |
monocytes of peripheral blood |
Treatment: treated with DMSO (Veh control) for 4 hours; Source: Adult Human Peripheral Blood; Donor:Buffycoat 12; |
Permissive
|
Homo sapiens |
GSE109438
...
|
MA0113.3
|
NR3C1 |
monocytes of peripheral blood |
Treatment: treated with 1 micromolar (1uM) TA for 4 hours; Source: Adult Human Peripheral Blood; Donor:Buffycoat 12; |
Permissive
Robust
|
Homo sapiens |
GSE109438
...
|
MA0113.3
|
NR3C1 |
macrophages |
Treatment: treated with DMSO (Veh control) for 4 hours; Source: Adult Human Peripheral Blood; Donor:Buffycoat 11; |
Permissive
|
Homo sapiens |
GSE109438
...
|
MA0113.3
|
NR3C1 |
macrophages |
Treatment: treated with 1 micromolar (1uM) TA for 4 hours; Source: Adult Human Peripheral Blood; Donor:Buffycoat 11; |
Permissive
Robust
|
Homo sapiens |
GSE109438
...
|
MA0113.3
|
NR3C1 |
MEF (mouse embryonic fibroblasts) |
Treatment: Dexamethasone 100 nM for 1 hr; Genotype: knockout of endogenous GR; |
Permissive
Robust
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
3617-KOGR (mouse adenocarcinoma) |
Treatment: no treatment; Genotype: knockout of endogenous GR; |
Permissive
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
3617-KOGR (mouse adenocarcinoma) |
Treatment: no treatment; Genotype: knockout of endogenous GR; |
Permissive
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
3617-KOGR (mouse adenocarcinoma) |
Treatment: no treatment; Genotype: knockout of endogenous GR, stably expressing GFP-GR; |
Permissive
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
3617-KOGR (mouse adenocarcinoma) |
Treatment: Dexamethasone 100 nM for 1 hr; Genotype: knockout of endogenous GR, stably expressing GFP-GR; |
Permissive
Robust
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
3617-KOGR (mouse adenocarcinoma) |
Treatment: no treatment; Genotype: knockout of endogenous GR, stably expressing GFP-GR; |
Permissive
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
3617-KOGR (mouse adenocarcinoma) |
Treatment: Dexamethasone 100 nM for 1 hr; Genotype: knockout of endogenous GR, stably expressing GFP-GR; |
Permissive
Robust
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
3617-KOGR (mouse adenocarcinoma) |
Treatment: no treatment; Genotype: knockout of endogenous GR, stably expressing P481R GFP-GRtetra; |
Permissive
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
3617-KOGR (mouse adenocarcinoma) |
Treatment: Dexamethasone 100 nM for 1 hr; Genotype: knockout of endogenous GR, stably expressing P481R GFP-GRtetra; |
Permissive
Robust
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
MEF (mouse embryonic fibroblasts) |
Treatment: Dexamethasone 100 nM for 1 hr; Genotype: knockout of endogenous GR; |
Permissive
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
MEF (mouse embryonic fibroblasts) |
Treatment: Dexamethasone 100 nM for 1 hr; Genotype: knockout of endogenous GR, stably expressing GFP-GR; |
Permissive
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
MEF (mouse embryonic fibroblasts) |
Treatment: no treatment; Genotype: knockout of endogenous GR, stably expressing P481R GFP-GRtetra; |
Permissive
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
MEF (mouse embryonic fibroblasts) |
Treatment: Dexamethasone 100 nM for 1 hr; Genotype: knockout of endogenous GR, stably expressing P481R GFP-GRtetra; |
Permissive
Robust
|
Mus musculus |
GSE108634
...
|
MA0113.3
|
NR3C1 |
BWTG3(Hepatocellular carcinoma of the mouse) |
Treatment: none; |
Permissive
|
Mus musculus |
GSE123953
...
|
MA0113.3
|
NR3C1 |
BWTG3(Hepatocellular carcinoma of the mouse) |
Treatment: 1uM Dex (Sigma, D-2915) for 3 hrs; |
Permissive
Robust
|
Mus musculus |
GSE123953
...
|
MA0113.3
|
NR3C1 |
BWTG3(Hepatocellular carcinoma of the mouse) |
Treatment: 1uM Dex (Sigma, D-2915) and 1000u/ml recombinant TNF for 3 hrs; |
Permissive
|
Mus musculus |
GSE123953
...
|
MA0113.3
|
NR3C1 |
BWTG3(Hepatocellular carcinoma of the mouse) |
Treatment: 1000u/ml recombinant TNF for 3 hrs; |
Permissive
|
Mus musculus |
GSE123953
...
|
MA0113.3
|
NR3C1 |
IMR90 (lung fibroblasts) |
GLUCC |
Permissive
Robust
|
Homo sapiens |
ERP007081
|
MA0113.3
|
NR3C1 |
K562 (myelogenous leukemia) |
GLUCC |
Permissive
|
Homo sapiens |
ERP007081
|
MA0113.3
|
NR3C1 |
U2OS (osteosarcoma) |
GLUCC |
Permissive
Robust
|
Homo sapiens |
ERP007081
|
MA0113.3
|
NR3C1 |
|
DMI |
Permissive
Robust
|
Homo sapiens |
GSE68864
|
MA0113.3
|
NR3C1 |
RS4-11 (adult B acute lymphoblastic leukemia) |
DEX |
Permissive
Robust
|
Homo sapiens |
GSE71616
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
|
Permissive
|
Homo sapiens |
ENCSR116TFA
|
MA0113.3
|
NR3C1 |
GM12878 (female B-cells lymphoblastoid cell line) |
|
Permissive
|
Homo sapiens |
ENCSR904YPP
|
MA0113.3
|
NR3C1 |
K562 (myelogenous leukemia) |
|
Permissive
|
Homo sapiens |
ENCSR325DER
|
MA0113.3
|
NR3C1 |
A549 (lung carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR355HLV
|
MA0113.3
|
NR3C1 |
K562 (myelogenous leukemia) |
|
Permissive
|
Homo sapiens |
ENCSR494UQJ
|
MA0113.3
|
NR3C1 |
3T3-L1-derived preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE21898
...
|
MA0113.3
|
NR3C1 |
MDA-MB-231 (breast adenocarcinoma) |
|
Permissive
|
Homo sapiens |
GSE56022
...
|
MA0113.3
|
NR3C1 |
acute myeloblastic leukemia |
|
Permissive
|
Homo sapiens |
GSE58266
...
|
MA0113.3
|
NR3C1 |
3134 (mammary adenocarcinoma) |
|
Permissive
|
Mus musculus |
GSE61234
...
|
MA0113.3
|
NR3C1 |
monocyte-derived macrophages |
|
Permissive
Robust
|
Homo sapiens |
GSE61878
...
|
MA0113.3
|
NR3C1 |
burst-forming unit erythroid |
|
Permissive
|
Mus musculus |
GSE62788
...
|
MA0113.3
|
NR3C1 |
white adipose tissue |
|
Permissive
Robust
|
Mus musculus |
GSE64458
...
|
MA0113.3
|
NR3C1 |
epididymal white adipose tissue |
|
Permissive
Robust
|
Mus musculus |
GSE64458
...
|
MA0113.3
|
NR3C1 |
embryonic fibroblasts |
|
Permissive
|
Mus musculus |
GSE69947
...
|
MA0113.3
|
NR3C1 |
brown preadipocytes |
|
Permissive
|
Mus musculus |
GSE76619
...
|
MA0113.3
|
NR3C1 |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE76619
...
|
MA0113.3
|
NR3C1 |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE76619
...
|
MA0113.3
|
NR3C1 |
HepG2 (hepatoblastoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE85343
...
|
MA0113.3
|
NR3C1 |
MM1.S (plasma cell myeloma) |
|
Permissive
|
Homo sapiens |
GSE63209
|
MA0113.3
|
NR3C1 |
|
DMSO |
Permissive
|
Homo sapiens |
GSE24518
|
MA0113.3
|
NR3C1 |
|
GRKD_DMSO |
Permissive
|
Homo sapiens |
GSE24518
|
MA0113.3
|
NR3C1 |
|
GRKD_TA_TNFA |
Permissive
|
Homo sapiens |
GSE24518
|
MA0113.3
|
NR3C1 |
|
P65KD_DMSO |
Permissive
|
Homo sapiens |
GSE24518
|
MA0113.3
|
NR3C1 |
|
P65KD_TA_TNFA |
Permissive
Robust
|
Homo sapiens |
GSE24518
|
MA0113.3
|
NR3C1 |
|
TA |
Permissive
Robust
|
Homo sapiens |
GSE24518
|
MA0113.3
|
NR3C1 |
|
TA_TNFA |
Permissive
Robust
|
Homo sapiens |
GSE24518
|
MA0113.3
|
NR3C1 |
|
TNFA |
Permissive
|
Homo sapiens |
GSE24518
|
MA0113.3
|
NR3C1 |
LNCaP (prostate carcinoma) |
1F5 |
Permissive
Robust
|
Homo sapiens |
GSE30623
|
MA0113.3
|
NR3C1 |
LNCaP (prostate carcinoma) |
1F5_SIFOXA1 |
Permissive
Robust
|
Homo sapiens |
GSE30623
|
MA0113.3
|
NR3C1 |
LCL (lymphoblastoid cell line) |
DEX |
Permissive
|
Homo sapiens |
GSE45638
|
MA0113.3
|
NR3C1 |
LCL (lymphoblastoid cell line) |
ETOH |
Permissive
|
Homo sapiens |
GSE45638
|
MA0113.3
|
NR3C1 |
U2OS (osteosarcoma) |
SHHIC5 |
Permissive
Robust
|
Homo sapiens |
GSE65847
|
MA0113.3
|
NR3C1 |
U2OS (osteosarcoma) |
SHNS |
Permissive
Robust
|
Homo sapiens |
GSE65847
|
MA0113.3
|
NR3C1 |
NALM-6 (adult B acute lymphoblastic leukemia) |
CASP1 |
Permissive
Robust
|
Homo sapiens |
GSE67046
|
MA0113.3
|
NR3C1 |
MCF7 (Invasive ductal breast carcinoma) |
DEX |
Permissive
Robust
|
Homo sapiens |
GSE72249
|
MA0113.3
|
NR3C1 |
T47D (invasive ductal carcinoma) |
DEX |
Permissive
Robust
|
Homo sapiens |
GSE72249
|
MA0113.3
|
NR3C1 |
ZR-75-1 (invasive ductal carcinoma) |
DEX |
Permissive
Robust
|
Homo sapiens |
GSE72249
|
MA0113.3
|
NR3C1 |
NALM-6 (adult B acute lymphoblastic leukemia) |
|
Permissive
Robust
|
Homo sapiens |
GSE67046
|
MA0113.3
|
NR3C1 |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
|
Homo sapiens |
GSE72249
|
MA0113.3
|
NR3C1 |
T47D (invasive ductal carcinoma) |
|
Permissive
|
Homo sapiens |
GSE72249
|
MA0113.3
|
NR3C1 |
ZR-75-1 (invasive ductal carcinoma) |
|
Permissive
|
Homo sapiens |
GSE72249
|
MA0113.3
|
NR3C1 |
IMR90 (lung fibroblasts) |
|
Permissive
Robust
|
Homo sapiens |
ERP007093
|
MA0113.3
|
NR3C1 |
IMR90 (lung fibroblasts) |
|
Permissive
|
Homo sapiens |
ERP007093
|
MA0113.3
|